All In Biotech

Drug Trial Radar · NCT05461573

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

A Phase 3, Multi-Center, Non-Comparative Study to Evaluate the Contraceptive Efficacy, Safety, and Tolerability of LPRI-CF113 Administered Orally for 13 Medication Cycles

Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,542

Actual

Start

Aug 2, 2022

Primary completion

Aug 5, 2024

Study completion May 27, 2025

Sponsor

Lead sponsor
Insud PharmaIndustry
Sponsor type
Industry
Collaborators
Chemo Research
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 13 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The secondary objective of Part A is to evaluate the safety and tolerability of LPRI-CF113. The primary objective of Part B is to evaluate the impact of LPRI-CF113 on bone mineral density (BMD) at the lumbar spine (L1-L4) after 12 months (13 medication cycles). The secondary objective of Part B is to evaluate the impact of LPRI-CF113 on BMD and bone turnover after 12 months (13 medication cycles) at the femoral neck, total hip, and total body.

Conditions

  • Contraception
  • Change in Bone Mineral Density

Interventions

  • DrospirenoneDrug

    LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Efficacy Assessment): Number of pregnancies in subjects ≤35 years of age (at the time of screening).Time frame: 12 months

Locations

47 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, LLC

    Alabaster, Alabama

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama

  • Del Sol Research Management

    Tucson, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Cornerstone Research Institute - Longwood

    Altamonte Springs, Florida

  • Encore Medical Research of Boynton Beach LLC.

    Boynton Beach, Florida

  • Women's Medical Research Group

    Clearwater, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Inpatient Research Clinic, LLC

    Hialeah, Florida

  • Vital Pharma Research, Inc.

    Hialeah, Florida

  • Encore Medical Research, LLC

    Hollywood, Florida

  • Global Research Associates

    Homestead, Florida

  • Altus Research

    Lake Worth, Florida

  • Florida International Medical Research

    Miami, Florida

  • New Age Medical Research Corporation

    Miami, Florida

  • SJ Research Institute

    Miami, Florida

  • Segal Institute for Clinical Research

    North Miami, Florida

  • American Research Centers of Florida

    Pembroke Pines, Florida

  • Comprehensive Clinical Trials

    West Palm Beach, Florida

  • Encore Medical Research of Weston LLC

    Weston, Florida

  • Fellows Research Alliance

    Savannah, Georgia

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Leavitt Clinical Research

    Idaho Falls, Idaho

  • Rosemark WomenCare Specialists

    Idaho Falls, Idaho

  • Praetorian Pharmaceutical Research

    Marrero, Louisiana

  • Southern Clinical Research Associates

    Metairie, Louisiana

  • Eastern Clinical Research Associates

    New Orleans, Louisiana

  • Eastern Carolina Women's Center

    New Bern, North Carolina

  • Unified Women's Clinical Research - Raleigh

    Raleigh, North Carolina

  • Unified Women's Clinical Research - Winston-Salem

    Winston-Salem, North Carolina

  • Clinohio Research Services

    Columbus, Ohio

  • AC Clinical Research

    Tiffin, Ohio

  • Clinical Research of Philadelphia

    Philadelphia, Pennsylvania

  • The Research Center of the Upstate

    Greenville, South Carolina

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Chattanooga Medical Research

    Chattanooga, Tennessee

  • Central Texas Clinical Research

    Austin, Texas

  • Discovery Clinical Trials

    Dallas, Texas

  • TMC Life Research

    Houston, Texas

  • FMC Science

    Lampasas, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.